September 17, 2012 -- BASF will present its extensive expertise across the entire
pharmaceutical value chain at the Convention on Pharmaceutical
Ingredients and Intermediates – CPhI worldwide – from October 9-
11, 2012 at Booth 4D17, Hall 4, Feria de Madrid, Spain. Taking
center stage of this year’s booth is BASF’s new strategy “We create
chemistry”. The company exhibits intelligent end-to-end solutions
and high-quality products including active pharmaceutical
ingredients (APIs), custom synthesis, excipients, catalysts, building
blocks, solvents, reagents, protective groups and inorganic
specialties.
First Class APIs from the world leader
For more than 75 years, BASF has been the world-leading supplier
of generic active ingredients to the pharmaceutical industry. The
company has, for example, manufactured ibuprofen for two
decades, deploying an award-winning sustainable production
technique that does not use chromium salts. Furthermore, BASF’s
broad range of APIs includes caffeine, pseudoephedrine,
theophylline, and phenylephrine. In 2013, BASF will extend its
portfolio by introducing a pharmaceutical grade of L-menthol to the
market.
Highly concentrated omega-3 fatty acids
With the recent acquisition of Equateq Ltd., a global leader in the
manufacturing of highly concentrated omega-3 fatty acids, BASF
broadened its range of omega-3 products for the pharmaceutical
and dietary supplement industries. The company’s proprietary
chromatographic separation methods allow flexible formulation of
omega-3 fatty acids with variable ratios of EPA (eicosapentaenoic
acid) and DHA (docosahexaenoic acid) at concentration levels of up
to 99 percent.
Custom synthesis services – Expertise in meeting unique
manufacturing needs
BASF is a leading manufacturer of made-to-measure molecules for
the pharmaceutical industry. Offering high-quality and cost-effective
services, the company supports customers throughout the entire
drug life cycle. Partnering with BASF gives customers access to a
global Research & Development network where value-added
technologies are constantly emerging – offering innovative solutions
for simplifying production processes and cutting costs.
Innovative excipients for bioavailability enhancement
BASF provides pharmaceutical companies a wide variety of
excipients for making drugs from active ingredients with tremendous
potential. One example is its award-winning solubilizing agent
Soluplus® - The Solid Solution. Soluplus enhances the solubility of
drugs and so increases their bioavailability. The product is ideal for
innovative pharmaceutical process technologies such as Hot Melt
Extrusion (HME) and Spray Drying. BASF has made great strides in
enhancing the solubilization and bioavailability of drugs during
recent years, developing innovative solutions for even the toughest
solubilization challenges.
New edition of Hot-Melt Extrusion Compendium available soon
A new edition of BASF’s Hot-Melt Extrusion Compendium –
delivering expert advice on creating solid dispersions using BASF
pharmaceutical-grade polymers – will be available for download as
of October 9. The previous edition has been revised, and many parts
have been extended: The compendium will provide readers with an
even better understanding of solid dispersions and the hot-melt
extrusion process. The publication will be available for download at
www.innovate-excipients.basf.com
New reagent for Suzuki coupling partners
BASF has introduced Tetrakis (dimethylamino)diboron as a new
reagent for borylation to generate coupling partners for Suzuki
reactions. Tetrakis DMA4B2 together with a diol enables the
borylation of a broad spectrum of substrates. The borylation with
Tetrakis DMA4B2 works with a broad variety of different solvents
and catalysts. Tetrakis DMA4B2 is a pumpable liquid, which makes
borylations at higher concentrations and even solvent-free reaction
possible. Therefore, space-time yield and reactor utilization will be
optimized. BASF’s Tetrakis DMA4B2 is available in quantities
ranging from kilograms to commercial scale.
Unique expertise in biomarker discovery
Metanomics Health GmbH, a BASF Group company, offers most
robust and reproducible results for biomarker discovery and
validation based on the globally largest metabolomics platform. In
the development of novel drugs, early recognition of potential
toxicological effects and their underlying mechanisms is of utmost
importance. To support the cost- and time-effective development of
new active pharmaceutical ingredients with more favorable
toxicological profiles, Metanomics Health has launched
MetaMap®Tox in June 2012, a validated in vivo product for
biopharmaceutical safety research.